179 related articles for article (PubMed ID: 14977581)
1. Antisense therapeutics and the treatment of CNS disease.
Jaeger LB; Banks WA
Front Biosci; 2004 May; 9():1720-7. PubMed ID: 14977581
[TBL] [Abstract][Full Text] [Related]
2. The potential of antisense as a CNS therapeutic.
Godfray J; Estibeiro P
Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases.
Forte A; Cipollaro M; Cascino A; Galderisi U
Curr Drug Targets; 2005 Feb; 6(1):21-9. PubMed ID: 15720210
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
[TBL] [Abstract][Full Text] [Related]
5. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Sarin H
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
[TBL] [Abstract][Full Text] [Related]
6. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
9. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides for central nervous system tumors.
Hall WA; Flores EP; Low WC
Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
Boado RJ; Tsukamoto H; Pardridge WM
J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
[TBL] [Abstract][Full Text] [Related]
12. Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections.
Metz T; Kuijper EC; van Roon-Mom WMC
Methods Mol Biol; 2022; 2434():333-341. PubMed ID: 35213029
[TBL] [Abstract][Full Text] [Related]
13. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
[TBL] [Abstract][Full Text] [Related]
14. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
Bennett CF; Swayze EE
Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
[TBL] [Abstract][Full Text] [Related]
15. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
Bishop KM
Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
[TBL] [Abstract][Full Text] [Related]
16. Perspectives in antisense therapeutics.
Agrawal S; Iyer RP
Pharmacol Ther; 1997; 76(1-3):151-60. PubMed ID: 9535177
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide therapy in cancer.
Stephens AC; Rivers RP
Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
Danis RP; Henry SP; Ciulla TA
Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
[TBL] [Abstract][Full Text] [Related]
20. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
Phillips MI
Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
